Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
39
SLNCF Quote, Financials, Valuation and Earnings
Last price:
$1.60
Seasonality move
:
18.36%
Day range:
$1.60 - $1.60
52-week range:
$0.50 - $2.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
112.71x
P/B ratio:
3.06x
Volume:
--
Avg. volume:
172
1-year change:
6.67%
Market cap:
$226.7M
Revenue:
$43.3M
EPS (TTM):
-$0.79
Analysts' Opinion
-
Consensus RatingSilence Therapeutics Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Silence Therapeutics Plc has an estimated downside of -- from its current price of $1.60.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $1.60.
Fair Value
-
According to the consensus of 1 analyst, Silence Therapeutics Plc has -- downside to fair value with a price target of -- per share.
SLNCF vs. S&P 500
-
Over the past 5 trading days, Silence Therapeutics Plc has underperformed the S&P 500 by -0.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Silence Therapeutics Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Silence Therapeutics Plc revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Silence Therapeutics Plc reported revenues of $159K.
Earnings Growth
-
Silence Therapeutics Plc earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Silence Therapeutics Plc reported earnings per share of -$0.15.
Enterprise value:
124.7M
EV / Invested capital:
--
Price / LTM sales:
112.71x
EV / EBIT:
--
EV / Revenue:
62.06x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-1.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.1M
Return On Assets:
-58.13%
Net Income Margin (TTM):
-5571.16%
Return On Equity:
-101.79%
Return On Invested Capital:
-101.67%
Operating Margin:
-14881.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $34.3M | $20.5M | $2M | $1.5M | $159K | |
| Gross Profit | $18.4M | $9.1M | -$2.1M | -$2.1M | -$20.5K | |
| Operating Income | -$58M | -$72M | -$99M | -$29.3M | -$23.7M | |
| EBITDA | -$57.4M | -$71.4M | -$98.4M | -$29.1M | -$23.5M | |
| Diluted EPS | -$0.48 | -$0.56 | -$0.79 | -$0.25 | -$0.15 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $111.6M | $126.7M | $106.9M | $211.3M | $133.6M | |
| Total Assets | $124.5M | $138.5M | $119.5M | $227.2M | $146.8M | |
| Current Liabilities | $24.7M | $28.9M | $22M | $22.7M | $17.4M | |
| Total Liabilities | $102.6M | $100.4M | $95.1M | $100.4M | $72.7M | |
| Total Equity | $22M | $38.1M | $24.4M | $126.8M | $74.1M | |
| Total Debt | -- | $557K | $384.4K | $186.4K | $97K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.2M | -$53.6M | -$71.1M | -$25M | -$11M | |
| Cash From Investing | $375.6K | -$88.1M | -$32.6M | -$38.1M | $52.8M | |
| Cash From Financing | $19.3M | $154.2M | $7.8M | $7.8M | -$100 | |
| Free Cash Flow | -$49.6M | -$53.8M | -$71.2M | -$25M | -$11M | |
SLNCF
Sector
Market Cap
$226.7M
--
Price % of 52-Week High
71.11%
--
Dividend Yield
0%
--
Shareholder Yield
-3.8%
--
1-Year Price Total Return
6.67%
--
Beta (5-Year)
0.776
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.60
200-day SMA
Buy
Level
$1.56
Bollinger Bands (100)
Sell
Level
1.42 - 1.9
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$1.50
Relative Strength Index (RSI14)
Buy
Level
53.60
ADX Line
Neutral
Level
Williams %R
Sell
Level
0
50-day SMA
Sell
Level
$1.68
MACD (12, 26)
Buy
Level
0.44
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.393)
Sell
CA Score
(Annual)
Level (-1.8198)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.0818)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
Stock Forecast FAQ
In the current month, SLNCF has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLNCF average analyst price target in the past 3 months is --.
-
Where Will Silence Therapeutics Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Silence Therapeutics Plc share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Silence Therapeutics Plc?
Analysts are divided on their view about Silence Therapeutics Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Silence Therapeutics Plc is a Sell and believe this share price will rise from its current level to --.
-
What Is Silence Therapeutics Plc's Price Target?
The price target for Silence Therapeutics Plc over the next 1-year time period is forecast to be -- according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SLNCF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Silence Therapeutics Plc is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SLNCF?
You can purchase shares of Silence Therapeutics Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Silence Therapeutics Plc shares.
-
What Is The Silence Therapeutics Plc Share Price Today?
Silence Therapeutics Plc was last trading at $1.60 per share. This represents the most recent stock quote for Silence Therapeutics Plc. Yesterday, Silence Therapeutics Plc closed at $1.60 per share.
-
How To Buy Silence Therapeutics Plc Stock Online?
In order to purchase Silence Therapeutics Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SLNCF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SLNCF
Sector
P/E ratio
--
--
PEG ratio
-0.02x
--
P/B ratio
3.06x
--
Price / LTM sales
112.71x
--
Growth Metrics
SLNCF
Sector
Revenue growth
-78.93%
--
Earnings growth
-5.64%
--
Revenue (5-year growth)
168.28%
--
Earnings forecast
-$0.15
--
Profitability
SLNCF
Sector
Profitability FY 2024
$31.2M
--
Return on invested capital
-101.67%
--
Return on assets
-58.13%
--
Return on equity
-101.79%
--
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
SLNCF
Sector
Total cash
$102.2M
--
Short term investments
$26M
--
Total assets
$202.6M
--
Long term debt
$97K
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
